title: FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.
abstract: We report 2 patients with chronic myeloid leukemia in the chronic phase showing diffusely increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment. Follow-up FDG positron emission tomography (PET) scans were performed in a patient after cessation of treatment and in the other under treatment. Both FDG PET findings showed reduced FDG uptake in the bone marrow. A series of these FDG PET findings suggest the usefulness of FDG PET for the diagnosis and monitoring of chronic myeloid leukemia after treatment.
authors: Department of Radiology, Atsuchi Memorial Clinic PET Center, Kagoshima, Japan. toyo.nakajo@dolphin.ocn.ne.jp
authors: Masatoyo
authors: M
authors: Nakajo
authors: Seishi
authors: S
authors: Jinnouchi
authors: Hirosaka
authors: H
authors: Inoue
authors: Maki
authors: M
authors: Otsuka
authors: Tadashi
authors: T
authors: Matsumoto
authors: Toshimasa
authors: T
authors: Kukita
authors: Hiroaki
authors: H
authors: Tanabe
authors: Rie
authors: R
authors: Tateno
authors: Masayuki
authors: M
authors: Nakajo
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000068877:Imatinib Mesylate